
Product Data Sheet

Product Name: Donanemab

Cat. No.: GC68996

Chemical Properties

Cas. No. 1931944-80-7

Formula M.Wt

Solubility Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure **Protocol****Animal experiment [1]:**

| | |
|--------------------|--|
| Animal models | Platelet-derived growth factor promoter-amyloid precursor protein (PDAPP) mouse model |
| Preparation Method | PDAPP mice were injected subcutaneously weekly for 6 months with 1.5, 4, and 12.5mg/kg of Donanemab. |
| Dosage form | 1.5, 4, and 12.5mg/kg; sc; 6 months |

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Applications

PDAPP mice treated with the Donanemab antibody showed a significant dose-dependent decrease in A β 42 levels in both the hippocampus and cortex.

References:

[1]. DeMattos RB, Lu J, Tang Y, et al. A plaque-specific antibody clears existing β -amyloid plaques in Alzheimer's disease mice. *Neuron*. 2012 Dec 6; 76(5): 908-920.

Background

Donanemab is a humanized IgG1 monoclonal antibody. Donanemab targets deposited A β 42, and clear amyloid plaques in the brain through microglia-mediated phagocytosis. Donanemab mainly localized in the plasma and extracellular space and penetrates the brain across the blood-brain barrier to bind A β deposits. Donanemab is an effective treatment for Alzheimer's disease [1-5].

In the platelet-derived growth factor promoter-amyloid precursor protein (PDAPP) mouse model, A β 42 levels in the hippocampus and cortex of mice were significantly reduced after Donanemab (1.5, 4, and 12.5mg/kg; sc; 6 months) treatment [6].

References:

- [1]. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. *Jama*. 2023 Aug 8; 330(6): 512-527.
- [2]. Mintun M, Ritchie CW, Solomon P, et al. Donanemab in Early Symptomatic Alzheimer's Disease: Efficacy and Safety in TRAILBLAZER-ALZ 2, a Phase 3 Randomized Clinical Trial. *Alzheimer's & Dementia*. 2023 Dec; 19: e082733.
- [3]. Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer's disease. *New England Journal of Medicine*. 2021 May 6; 384(18): 1691-1704.
- [4]. Jayaprakash N, Elumalai K. Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application. *Chronic Diseases and*

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Translational Medicine. 2024.

[5]. Kang C. Donanemab: first approval. *Drugs*. 2024 Oct; 84(10): 1313-1318.

[6]. DeMattos RB, Lu J, Tang Y, et al. A plaque-specific antibody clears existing β -amyloid plaques in Alzheimer's disease mice. *Neuron*. 2012 Dec 6; 76(5): 908-920.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA